AbbVie

Biotechnology
ABBV
$ 177 0.9
Share price
$ 312 bn
Market Cap
$ 357 bn
Enterprise Value

Carbon footprint

1.5 Ton
GHG emissions per $ 1 mln investment
0.04x the weighted average for S&P 500
FY2022
How is this calculated?
-16%
YOY change in GHG emissions
Weaker than the +0.5% weighted average for S&P 500
FY2022 vs. previous year

Primary Climate Goal

-3.9%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -8.2% weighted average for S&P 500
FY2023
How is this calculated?

AbbVie aims to reduce Scope 1 + 2 by 42% by 2030 from a base year 2021


1.5°C
AbbVie's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

AbbVie's GHG emissions (market-based) (Kt of CO2e)

AbbVie's carbon footprint

AbbVie reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2022 at 527 Kt (-98 /-15.6% y-o-y).

No public disclosure of Scope 3 emissions has been found for AbbVie at the moment.

The company is committed to reducing Scope 1 + 2 by 42% by 2030 from a base year 2021, which translates into the estimated reduction of -21 Kt per annum over the period of FY2023 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...